Literature DB >> 10192767

GGF/neuregulin induces a phenotypic reversion of oligodendrocytes.

P D Canoll1, R Kraemer, K K Teng, M A Marchionni, J L Salzer.   

Abstract

We have previously shown that glial growth factor (GGF), a member of the neuregulin (NRG) family of growth factors, is a mitogen and survival factor for oligodendrocyte progenitors in cell culture and blocks their differentiation at the pro-oligodendrocyte stage (P. D. Canoll et al., 1996, Neuron 17, 229-243). We now show that GGF is able to induce differentiated oligodendrocytes to undergo a phenotypic reversion characterized by loss of MBP expression, reexpression of the intermediate filament protein nestin, reorganization of the actin cytoskeleton, and a dramatic reduction in the number of processes per cell. TUNEL analysis demonstrates that GGF is not cytotoxic for mature oligodendrocytes, but rather enhances their survival. GGF also induces the rapid activation of the PI 3-kinase and MAP kinase signaling pathways. These results further support a role for the NRGs in promoting the proliferation and survival of and inhibiting the differentiation of cells in the oligodendrocyte lineage and demonstrate that oligodendrocytes that differentiate in culture retain a substantial degree of phenotypic plasticity. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10192767     DOI: 10.1006/mcne.1998.0733

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN: 1044-7431            Impact factor:   4.314


  28 in total

1.  Akt-mediated survival of oligodendrocytes induced by neuregulins.

Authors:  A I Flores; B S Mallon; T Matsui; W Ogawa; A Rosenzweig; T Okamoto; W B Macklin
Journal:  J Neurosci       Date:  2000-10-15       Impact factor: 6.167

2.  Adenosine: a neuron-glial transmitter promoting myelination in the CNS in response to action potentials.

Authors:  Beth Stevens; Stefania Porta; Laurel L Haak; Vittorio Gallo; R Douglas Fields
Journal:  Neuron       Date:  2002-12-05       Impact factor: 17.173

Review 3.  Axonal signals and oligodendrocyte differentiation.

Authors:  Maura Bozzali; Lawrence Wrabetz
Journal:  Neurochem Res       Date:  2004-05       Impact factor: 3.996

4.  Neuregulin-1 enhances survival of human astrocytic glioma cells.

Authors:  Patricia S Ritch; Steven L Carroll; Harald Sontheimer
Journal:  Glia       Date:  2005-08-15       Impact factor: 7.452

Review 5.  Multiple system atrophy: cellular and molecular pathology.

Authors:  D J Burn; E Jaros
Journal:  Mol Pathol       Date:  2001-12

6.  Strength of ERK1/2 MAPK Activation Determines Its Effect on Myelin and Axonal Integrity in the Adult CNS.

Authors:  Akihiro Ishii; Miki Furusho; Jeffrey L Dupree; Rashmi Bansal
Journal:  J Neurosci       Date:  2016-06-15       Impact factor: 6.167

Review 7.  Impact of neuregulin-1 on the pathophysiology of schizophrenia in human post-mortem studies.

Authors:  Andrea Schmitt; Eleni Parlapani; Oliver Gruber; Thomas Wobrock; Peter Falkai
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-11       Impact factor: 5.270

8.  Neuregulin-1/ErbB signaling serves distinct functions in myelination of the peripheral and central nervous system.

Authors:  Bastian G Brinkmann; Amit Agarwal; Michael W Sereda; Alistair N Garratt; Thomas Müller; Hagen Wende; Ruth M Stassart; Schanila Nawaz; Christian Humml; Viktorija Velanac; Konstantin Radyushkin; Sandra Goebbels; Tobias M Fischer; Robin J Franklin; Cary Lai; Hannelore Ehrenreich; Carmen Birchmeier; Markus H Schwab; Klaus Armin Nave
Journal:  Neuron       Date:  2008-08-28       Impact factor: 17.173

9.  Sustained activation of ERK1/2 MAPK in oligodendrocytes and schwann cells enhances myelin growth and stimulates oligodendrocyte progenitor expansion.

Authors:  Akihiro Ishii; Miki Furusho; Rashmi Bansal
Journal:  J Neurosci       Date:  2013-01-02       Impact factor: 6.167

10.  Constitutive EGFR signaling in oligodendrocyte progenitors leads to diffuse hyperplasia in postnatal white matter.

Authors:  Sanja Ivkovic; Peter Canoll; James E Goldman
Journal:  J Neurosci       Date:  2008-01-23       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.